Pase10 ml

Pase 10 ml is indicated for the treatment of panic disorder, with or without agoraphobia. Panic disorder involves recurring, unexpected panic attacks along with persistent worry about future attacks and their consequences.

Pase 10 ml is also used, either alone or as an adjunct therapy, for the following seizure disorders:

• Lennox-Gastaut syndrome (petit mal variant)
• Akinetic seizures
• Myoclonic seizures
• Absence seizures (petit mal) that have not responded adequately to succinimide medications

The long-term effectiveness of Pase 10 ml (beyond 9 weeks of continuous use) has not been systematically evaluated in controlled clinical trials. Physicians prescribing Pase 10 ml for extended periods should periodically reassess whether continued therapy remains beneficial for the individual patient.

Adjunct anti-epileptic drugs, Benzodiazepine hypnotics

Pase 10 ml shares the pharmacological properties common to benzodiazepines, including anticonvulsant, sedative, muscle-relaxant, and anxiolytic (anti-anxiety) effects. Its central actions are mediated through enhancement of GABAergic neurotransmission at inhibitory synapses. In the presence of Pase 10 ml, the affinity of the GABA receptor for its neurotransmitter is increased through positive allosteric modulation, which boosts the postsynaptic transmembrane chloride ion flux triggered by released GABA. Animal studies also suggest an additional effect of Pase 10 ml on serotonin activity.

Animal studies and electroencephalographic (EEG) investigations in humans have shown that Pase 10 ml rapidly suppresses many types of paroxysmal activity, including spike-and-wave discharges in absence seizures, slow spike-wave patterns, generalized spike-wave discharges, and both temporal and irregular spike-and-wave activity. Generalized EEG abnormalities tend to respond more consistently than focal abnormalities, which is why Pase 10 ml is considered beneficial in both generalized and focal forms of epilepsy.

Pharmacokinetics

• Absorption: Pase 10 ml is well absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 4 hours.
• Protein binding: Approximately 82–86% bound to plasma proteins.
• Metabolism: Extensively metabolized in the liver, mainly via the CYP3A4 enzyme pathway, to inactive metabolites.
• Elimination half-life: Approximately 20 to 60 hours, which supports its long-acting profile.
• Excretion: Metabolites are primarily excreted in the urine.

Pase 10 ml does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital. Its effect on the metabolism of other drugs has not been formally investigated.

As with other benzodiazepines, caution is generally advised when Pase 10 ml is combined with:

• Other central nervous system (CNS) depressants, such as opioids, barbiturates, or sedative-hypnotics, as combined use may intensify sedation and respiratory depression
• Alcohol, which can significantly increase drowsiness and dizziness
• Valproic acid, which in combination with Pase 10 ml may precipitate absence status
• Strong CYP3A4 inhibitors or inducers, which may alter Pase 10 ml plasma levels due to its hepatic metabolism pathway

Patients should inform their doctor about all medications, supplements, and herbal products they are taking before starting Pase 10 ml therapy.

The most frequently occurring side effects of Pase 10 ml are related to central nervous system (CNS) depression. In patients treated for seizure disorders, drowsiness has been observed in approximately 50% of patients, and ataxia (loss of coordination) in approximately 30%. These effects may diminish over time in some patients. Behavior-related problems have been noted in approximately 25% of patients.

Other reported side effects include:

• Abnormal eye movements
• Aphonia (loss of voice)
• Coma
• Tremor
• Vertigo
• Confusion
• Depression
• Amnesia (memory impairment)
• Hallucinations
• Hysteria
• Increased libido
• Insomnia
• Psychosis
• Palpitations

Patients should report any unusual or bothersome symptoms to their physician promptly, especially changes in mood, behavior, or thoughts of self-harm.

Pregnancy

Preclinical studies cannot exclude the possibility that Pase 10 ml may produce congenital malformations. Epidemiological evaluations suggest that anticonvulsant drugs, as a class, may act as teratogens; however, it is often difficult to determine from published reports which specific drug or drug combination is responsible for birth defects. Other factors, such as genetics or the underlying epileptic condition itself, may also contribute to the risk.

Because of this, Pase 10 ml should only be given to pregnant women if the potential benefit clearly outweighs the risk to the fetus, and only when there is a compelling medical indication. Administration of high doses during the last trimester or during labor can cause irregular fetal heartbeat, and in the neonate may cause hypothermia, hypotonia (reduced muscle tone), mild respiratory depression, and poor feeding. Both pregnancy itself and abrupt discontinuation of Pase 10 ml can worsen epilepsy, so any changes in therapy should be made only under medical guidance. Withdrawal symptoms in newborns have occasionally been reported with benzodiazepine use during pregnancy.

Nursing Mothers

Although only small amounts of Pase 10 ml's active ingredient pass into breast milk, mothers undergoing Pase 10 ml treatment are generally advised not to breastfeed. If there is a compelling indication for continuing Pase 10 ml, breastfeeding should be discontinued.

In patients who have several different types of seizure disorders occurring together, Pase 10 ml may increase the frequency of, or precipitate, generalized tonic-clonic seizures. This may require the addition of appropriate anticonvulsant medications or an increase in their dosage.

The concomitant use of valproic acid with Pase 10 ml may produce absence status and should be monitored closely by a physician.

Additional general precautions to keep in mind:

• Pase 10 ml has a high potential for habit formation and dependence; it should be used only for the dose and duration advised by a doctor.
• Pase 10 ml may cause dizziness or drowsiness; avoid driving or operating machinery until the individual response to the medicine is known.
• Alcohol should be avoided, as it can intensify dizziness and drowsiness.
• Sudden discontinuation should be avoided, as it may lead to nausea, anxiety, agitation, flu-like symptoms, sweating, tremor, and confusion. Any dose changes should be made gradually under medical supervision.
• Patients should inform their doctor if they experience worsening anxiety, depression, anger, violent behavior, or mania while on this medicine.

Symptoms

Benzodiazepines, including Pase 10 ml, commonly cause drowsiness, ataxia, dysarthria (slurred speech), and nystagmus (involuntary eye movement) in overdose. Overdose of Pase 10 ml alone is seldom life-threatening, but it may lead to areflexia, apnoea, hypotension, cardiorespiratory depression, and coma. Coma, when it occurs, usually lasts a few hours but may be more protracted and cyclical, particularly in elderly patients. Increased seizure frequency may occur at supratherapeutic plasma concentrations. Respiratory depressant effects are more serious in patients with pre-existing respiratory disease, and benzodiazepines can intensify the effects of other CNS depressants, including alcohol.

Treatment

Management of Pase 10 ml overdose focuses on supportive care:

• Monitor the patient's vital signs and institute supportive measures based on the patient's clinical condition, particularly for cardiorespiratory or CNS effects.
• Prevent further absorption using an appropriate method, such as treatment with activated charcoal within 1–2 hours of ingestion. If activated charcoal is used, airway protection is essential for drowsy patients.
• In cases of mixed-drug ingestion, gastric lavage may be considered, though it is not used as a routine measure.
• If CNS depression is severe, the benzodiazepine antagonist flumazenil may be considered, but only under closely monitored conditions. Flumazenil has a short half-life (about one hour), so patients will require continued monitoring after its effects wear off. It must be used with extreme caution in patients also taking drugs that lower the seizure threshold, such as tricyclic antidepressants.

Any suspected overdose requires immediate emergency medical attention.

Keep in a dry place away from light and heat. Keep out of the reach of children.

Pediatric Use

In infants and small children, Pase 10 ml may cause increased production of saliva and bronchial secretions. Special attention must therefore be paid to maintaining a clear airway during treatment.

Geriatric Use

The pharmacologic effects of benzodiazepines, including Pase 10 ml, tend to be more pronounced in elderly patients compared to younger patients, even at similar plasma concentrations. This is possibly due to age-related changes in drug-receptor interactions, post-receptor mechanisms, and organ function. Lower starting doses and careful monitoring are generally advised in this age group.

Renal Impairment

Renal impairment does not affect the pharmacokinetics of Pase 10 ml. Based on pharmacokinetic criteria, no dose adjustment is required in patients with renal impairment.

Hepatic Impairment

Plasma protein binding of Pase 10 ml in cirrhotic patients differs significantly from that in healthy individuals (free fraction 17.1±1.0% vs. 13.9±0.2%). While the direct influence of hepatic impairment on Pase 10 ml pharmacokinetics has not been extensively studied, experience with the closely related drug nitrazepam suggests that clearance of unbound Pase 10 ml might be reduced in liver cirrhosis. Caution and dose adjustment may be needed in patients with hepatic impairment.

For slow intravenous injection, it's crucial to dilute the vial's contents with 1 ml of water for injection before administering to prevent irritation of the veins. This injection solution should be prepared just before use. During IV injection, it should be administered slowly while continuously monitoring EEG, respiration, and blood pressure.

When opting for intravenous infusion, Pase 10 ml (from the vial) can be diluted for infusion at a ratio of 1 vial (1 mg) to at least 85 ml of diluting media. Suitable diluting media options include sodium chloride 0.9%, sodium chloride 0.45% + glucose 2.5%, glucose 5%, or glucose 10%. These mixtures remain stable for 24 hours at room temperature. 

If PVC infusion bags are used, the mixture should be infused immediately or within 4 hours. The infusion should not exceed 8 hours. Avoid preparing Pase 10 ml infusions using sodium bicarbonate solution, as it may cause solution precipitation.

Intramuscular injection should be reserved for exceptional cases or when IV administration is not possible.

Adjunct anti-epileptic drugs, Benzodiazepine hypnotics

Pase 10 ml shares pharmacological properties common to benzodiazepines, encompassing anticonvulsive, sedative, muscle-relaxing, and anxiolytic effects. The central actions of benzodiazepines involve enhancing GABAergic neurotransmission at inhibitory synapses. In the presence of benzodiazepines, the GABA receptor's affinity for the neurotransmitter is boosted through positive allosteric modulation, resulting in an increased impact of released GABA on the postsynaptic transmembrane chloride ion flux.

Animal studies also indicate that this pill may affect serotonin. Both animal data and electroencephalographic investigations in humans have demonstrated that Pase 10 ml rapidly suppresses various forms of paroxysmal activity, including spike and wave discharges in absence seizures (petit mal), slow spike waves, generalized spike waves, spikes with temporal or other locations, as well as irregular spikes and waves. Generalized EEG abnormalities are more consistently suppressed than focal abnormalities. Based on these findings, Pase 10 ml offers beneficial effects in both generalized and focal epilepsies.

Pediatric Use: In infants and young children, the use of this medication may lead to increased saliva and bronchial secretions. Therefore, it's essential to ensure clear airways.

Geriatric Use: Elderly patients may experience more pronounced benzodiazepine effects compared to younger individuals, even with similar plasma benzodiazepine concentrations. This heightened sensitivity may result from age-related changes in drug-receptor interactions, post-receptor mechanisms, and organ function.

Renal Impairment: Renal issues do not affect the pharmacokinetics of this medication, necessitating no dosage adjustment for patients with kidney impairment.

Hepatic Impairment: In cirrhotic patients, the plasma protein binding of this medication significantly differs from that in healthy subjects, with a higher free fraction (17.1±1.0% vs. 13.9±0.2%). Although hepatic impairment's influence on Pase 10 ml pharmacokinetics hasn't been extensively studied, experience with a closely related nitrobenzodiazepine (nitrazepam) suggests that the clearance of unbound Pase 10 ml may be reduced in liver cirrhosis cases.